Zymeworks Inc. (ZYME) |
|
5.55 0.34 (6.53%)
|
05-16 08:44 |
|
Open: |
5.31 |
Pre. Close: |
5.21 |
|
High:
|
5.59 |
Low:
|
5.195 |
|
Volume:
|
1,147,289 |
Market Cap:
|
321(M) |
|
|
|
|
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.6 - 5.63 |
5.63 - 5.65 |
|
Low:
|
5.13 - 5.16 |
5.16 - 5.19 |
|
Close:
|
5.49 - 5.55 |
5.55 - 5.6 |
|
Technical analysis |
as of: 2022-05-16 8:22:55 AM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 7.72 One year: 9.2 |
| Support: |
Support1: 4.55 Support2: 3.79 |
| Resistance: |
Resistance1: 6.61 Resistance2: 7.88 |
| Pivot: |
5.78 |
| Moving Average: |
MA(5): 5.41 MA(20): 5.62
MA(100): 8.49  MA(250): 20.72 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 26.4 %D(3): 23.9 |
| RSI: |
RSI(14): 45.5 |
| 52-week: |
High: 39.4 Low: 4.55 |
| Average Vol(K): |
3-Month: 1,721 (K) 10-Days: 1,786 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ZYME ] has closed above bottom band by 42.2%. Bollinger Bands are 4.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Mon, 16 May 2022
Zacks: Brokerages Expect Zymeworks Inc. (NYSE:ZYME) Will Post Quarterly Sales of $7.56 Million - MarketBeat
Wed, 04 May 2022
Zymeworks Inc. (ZYME) CEO Kenneth Galbraith on Q1 2022 Results - Earnings Call Transcript - Seeking Alpha
Mon, 02 May 2022
Zymeworks Announces Participation in Upcoming Investor Conferences - Business Wire
Mon, 02 May 2022
Short Squeeze Stocks: HCDI, ZYME and 3 Others Experts Think Are Ready to Pop - InvestorPlace
Fri, 29 Apr 2022
Pre-Market Most Active for Apr 29, 2022 : FNCH, DIDI, ZYME, TQQQ, SQQQ, AAPL, NIO, BABA, QQQ, PDD, CTVA, BEKE - Nasdaq
Fri, 29 Apr 2022
Hot Stocks: Chinese internet stocks rise; ACCD drops 50%; VRSN sets low; ZYME jumps - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
47 (M) |
| Shares Float |
40 (M) |
|
% Held by Insiders
|
0.8 (%) |
|
% Held by Institutions
|
82.1 (%) |
|
Shares Short
|
6,020 (K) |
|
Shares Short P.Month
|
3,810 (K) |
Stock Financials |
|
EPS
|
-4.45 |
|
EPS Est Next Qtl
|
-0.68 |
|
EPS Est This Year
|
-2.99 |
|
EPS Est Next Year
|
-2.54 |
|
Book Value (p.s.)
|
5.98 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-944 |
|
Return on Assets (ttm)
|
-26.8 |
|
Return on Equity (ttm)
|
-59.3 |
|
Qtrly Rev. Growth
|
66.3 |
|
Gross Profit (p.s.)
|
-2.79 |
|
Sales Per Share
|
0.48 |
|
EBITDA (p.s.)
|
-4.48 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-190 (M) |
|
Levered Free Cash Flow
|
-146 (M) |
Stock Valuations |
|
PE Ratio
|
-1.25 |
|
PEG Ratio
|
-0.4 |
|
Price to Book value
|
0.92 |
|
Price to Sales
|
11.48 |
|
Price to Cash Flow
|
-1.37 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
